A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia

Inclusion Criteria: * Written informed consent must be obtained before admission in the study. * Patients in whom Candida species have been confirmed by 2 consecutive blood cultures within 12 hours. * Patients who have not received systemic administration of antifungal agents or who have started such administration within 48 hours prior to entry. * Patients who have hepatic and renal parameters within 2X ULN (upper level of normality) at screening. Exclusion Criteria: * Patients with a history of hypersensitivity to fluconazole or hLF1-11. * Patients who have been treated with fluconazole for at least 1 week within the previous 4 weeks. * Patients with a history of fluconazole-resistant Candida species within 12 weeks. * Neutropenic patients with neutrophil count below 0.5x10\^9/L. * Patients who are treated with terfenadine, triazolam, cisapride, and ergotamine, which are contraindicated for concomitant use with fluconazole. * Patients known to have AIDS or who are HIV-positive. * Females who have a positive pregnancy test at baseline or are capable of child-bearing i.e. without appropriate contraception (chemical or mechanical). * Patients with suspected candida osteomyelitis, endocarditis, or meningitis. * Patients who have received an investigational drug within three months prior to the study. * Patients with a concomitant medical condition, in whom, in the opinion of the Investigator, participation may create an unacceptable risk for the patient. * Patients considered inappropriate by the PI for enrollment in the study, for any reason.